CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM010606
Első szerző:Dankó Katalin (belgyógyász, allergológus és klinikai immunológus)
Cím:Paraneoplastic myopathy / Katalin Dankó, Andrea Ponyi, Andrew P. Molnar, Csilla András, Tamas Constantin
Dátum:2009
ISSN:1040-8711 (Print)
Megjegyzések:It has been recognized for some time now, that compared with the normal population, patients with idiopathic inflammatory myopathies (IIM) live with an increased risk of developing malignancy. In the majority of these patients, cancer-associated myositis appears to have some paraneoplastic features. The aim of the present review is to describe new data that explain the connection between myositis and malignant diseases, as well as to highlight its value in the current management of these patients. RECENT FINDINGS: Antigen expressions and patterns shared by regenerating muscle and cancers raise questions about whether myositis cases without clinically observable cancer may represent a fully successful antitumor immune response with bystander damage to regenerating muscle. The discovery of anti-155/140 autoantibody may aid in the better diagnosis of adult IIM patients with a higher risk of malignancy. It also may help the better understanding of paraneoplastic myositis. SUMMARY: Cancer-associated myositis differs from primary myositis in many aspects. Prognosis and life-expectancy are determined by the underlying malignancy. Therefore, patient-specific examinations for detection of an underlying cancer are important in the management of patients. Recent clinical findings and new possibilities in immunoserological testing may result in the elaboration of an evidence-based recommendation for cancer screening programs in patients with IIM in the future.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Current Opinion in Rheumatology. - 21 : 6 (2009), p. 594-598. -
További szerzők:Ponyi Andrea Molnár Andrew P. András Csilla (1961-) (onkológus szakorvos) Constantin Tamás
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM073042
Első szerző:Rider, Lisa G.
Cím:Myositis registries and biorepositories / Rider Lisa G., Dankó Katalin, Miller Frederick W.
Dátum:2014
ISSN:1040-8711
Megjegyzések:PURPOSE OF REVIEW:Clinical registries and biorepositories have proven extremely useful in many studies of diseases, especially rare diseases. Given their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndromes, have benefited from individual researchers' collections of cohorts of patients. Major efforts are being made to establish large registries and biorepositories that will allow many additional studies to be performed that were not possible before. Here, we describe the registries developed by investigators and patient support groups that are currently available for collaborative research purposes.RECENT FINDINGS:We have identified 46 myositis research registries, including many with biorepositories, which have been developed for a wide variety of purposes and have resulted in great advances in understanding the range of phenotypes, clinical presentations, risk factors, pathogenic mechanisms, outcome assessment, therapeutic responses, and prognoses. These are now available for collaborative use to undertake additional studies. Two myositis patient registries have been developed for research, and myositis patient support groups maintain demographic registries with large numbers of patients available to be contacted for potential research participation.SUMMARY:Investigator-initiated myositis research registries and biorepositories have proven extremely useful in understanding many aspects of these rare and diverse autoimmune diseases. These registries and biorepositories, in addition to those developed by myositis patient support groups, deserve continued support to maintain the momentum in this field as they offer major opportunities to improve understanding of the pathogenesis and treatment of these diseases in cost-effective ways.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
biorepository
dermatomyositis
idiopathic inflammatory myopathies
inclusion body myositis
juvenile dermatomyositis
myositis autoantibody
natural history
phenotype
polymyositis
registry
Megjelenés:Current Opinion In Rheumatology 26 : 6 (2014), p. 724-741. -
További szerzők:Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Miller, Frederick W.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM015870
Első szerző:Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:Angiogenesis and vasculogenesis in rheumatoid arthritis / Szekanecz, Z., Besenyei, T., Szentpetery, A., Koch, A. E.
Dátum:2010
ISSN:1531-6963 (Electronic)
Megjegyzések:Angiogenesis is the formation of new capillaries from pre-existing vessels, whereas vasculogenesis is de-novo capillary formation from endothelial precursor cells (EPCs). Current understanding of the role of angiogenesis and vasculogenesis in rheumatoid arthritis (RA) and possibilities of therapeutic intervention should be summarized. RECENT FINDINGS: There have been many recent studies on the role of the hypoxia and hypoxia-inducible factor (HIF)-vascular endothelial growth factor (VEGF)-angiopoietin axis in angiogenesis associated with RA. The role of additional growth factors, chemokines, cytokines, matrix components and adhesion molecules has been further characterized. Macrophage migration inhibitory factor (MIF) may link inflammation, angiogenesis and atherosclerosis. Junctional adhesion molecules (JAMs) and focal adhesion kinases (FAKs) have recently been implicated in inflammatory angiogenesis. Novel information regarding the role of serum amyloid A (SAA) and sphingosine kinase has become available. Most of these angiogenic factors have recently been targeted using various techniques and arthritis models. Whereas angiogenesis is abundant in RA, there is defective EPC function and vasculogenesis leading to atherosclerosis and vascular disease in arthritis. Treatment with EPCs already under investigation in vascular diseases may also be attempted in RA. SUMMARY: Targeting angiogenesis and restoration of vasculogenesis may be beneficial for the therapy and outcome of RA.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Angiogenesis Inhibitors/pharmacology/therapeutic use
Angiogenic Proteins/antagonists & inhibitors/metabolism
Arthritis/complications/metabolism/physiopathology
Arthritis, Rheumatoid/*complications/metabolism/*physiopathology
Blood Vessels/drug effects/metabolism/physiopathology
Endothelial Cells/drug effects/immunology/metabolism
Humans
Neovascularization, Pathologic/drug therapy/*immunology/*physiopathology
Vascular Diseases/drug therapy/*immunology/*physiopathology
Megjelenés:Current Opinion in Rheumatology. - 22 : 3 (2010), p. 299-306. -
További szerzők:Besenyei Tímea (1980-) (reumatológus, belgyógyász) Szentpétery Ágnes (1978-) (reumatológus) Koch, Alisa E.
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM007113
Első szerző:Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:Chemokines and angiogenesis / Szekanecz, Z., Koch, A. E.
Dátum:2001
ISSN:1040-8711 (Print)
Megjegyzések:Chemokines mediate the ingress of leukocytes, including neutrophils and monocytes, into the inflamed synovium. Among the four known chemokine families, C-X-C and C-C chemokines seem to be of outstanding importance in this process. Angiogenesis, the formation of new vessels, is also important in the pathogenesis of rheumatoid arthritis. In this review, the authors discuss the role of the most important chemokines in the pathogenesis of rheumatoid synovitis. The most relevant angiogenic factors and angiogenesis inhibitors involved in rheumatoid arthritis are also discussed. Because certain chemokines may also play a role in neovascularization, chemokines and the process of angiogenesis are described in this context as well. Apart from discussing the pathogenic role of these factors, the authors also review the important relevance of chemokines and angiogenesis for therapeutic intervention.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Antibodies
Arthritis, Rheumatoid
Chemokines
Humans
Neovascularization, Pathologic
Receptors, Chemokine
Megjelenés:Current Opinion in Rheumatology. - 13 : 3 (2001), p. 202-208. -
További szerzők:Koch, Alisa E.
Internet cím:elektronikus változat
elektronikus változat
Borító:

5.

001-es BibID:BIBFORM007121
Első szerző:Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:Macrophages and their products in rheumatoid arthritis / Szekanecz, Z., Koch, A. E.
Dátum:2007
ISSN:1040-8711 (Print)
Megjegyzések:Macrophages differentiate from peripheral-blood monocytes. Both monocytes and synovial macrophages are key players in rheumatoid arthritis. These cells are involved in the initiation and perpetuation of inflammation, leukocyte adhesion and migration, matrix degradation and angiogenesis. Macrophages express adhesion molecules, chemokine receptors and other surface antigens. They also secrete a number of chemokines, cytokines, growth factors, proteases and other mediators. RECENT FINDINGS: Macrophage migration-inhibitory factor has drawn significant attention recently. This cytokine is involved in macrophage activation and cytokine production. Migration-inhibitory factor also regulates glucocorticoid sensitivity and may be a pathogenic link between rheumatoid arthritis and atherosclerosis. Novel macrophage-derived chemokines and chemokine receptors have been identified. Interleukin-10 may have several proinflammatory effects that may influence its action in rheumatoid arthritis. Several proteinases including cathepsin G are produced by macrophages during rheumatoid arthritis-associated inflammatory and angiogenic events. Antirheumatic drugs, imatinib, chemokine receptor inhibitors and other specific strategies may become included in the therapy of rheumatoid arthritis. SUMMARY: Macrophages and their products are key players in the pathogenesis of rheumatoid arthritis and may be good therapeutic targets.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Animals
Antirheumatic Agents
Apoptosis
Arthritis, Experimental
Arthritis, Rheumatoid
Cell Adhesion Molecules
Cell Differentiation
Chemokines
Cytokines
Growth Substances
Humans
Macrophages
Mice
Neovascularization, Pathologic
Osteoclasts
Peptide Hydrolases
Protease Inhibitors
Receptors, Chemokine
Megjelenés:Current Opinion in Rheumatology. - 19 : 3 (2007), p. 289-295. -
További szerzők:Koch, Alisa E.
Internet cím:elektronikus változat
DOI
elektronikus változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.